Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship?
Curr Opin Allergy Clin Immunol
; 21(5): 411-417, 2021 10 01.
Article
in English
| MEDLINE | ID: covidwho-1337288
ABSTRACT
PURPOSE OF REVIEW Anaphylactic reactions reported after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) RNA vaccines were expected to be more frequent in atopic subjects and attributed to its polyethylene glycol component. RECENT FINDINGS:
Anaphylaxis to SARS-CoV2 RNA vaccines is no more frequent than in any vaccine and direct proofs for the role of its polyethylene glycol component are lacking.SUMMARY:
Vaccines against coronavirus disease 2019 (COVID-19) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have rapidly been reported after SARS-CoV2 RNA vaccines. This risk is now measured at 2.5-11/1 000 000 in the context of vaccine safety surveillance programs and only one case was documented to be due to polyethylene glycol. Suggestions for its role are indirect. The COVID-19 vaccination is rolling out vastly and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care, highlighting the key role of allergists in the vaccination programmes.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
Anaphylaxis
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Female
/
Humans
/
Male
Language:
English
Journal:
Curr Opin Allergy Clin Immunol
Journal subject:
Allergy and Immunology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS